BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Association of Health Care Journalists - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Association of Health Care Journalists
X-ORIGINAL-URL:https://healthjournalism.org
X-WR-CALDESC:Events for Association of Health Care Journalists
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250219T130000
DTEND;TZID=America/New_York:20250219T140000
DTSTAMP:20260413T153927
CREATED:20250210T184709Z
LAST-MODIFIED:20250220T161517Z
UID:58509-1739970000-1739973600@healthjournalism.org
SUMMARY:Decentralized: Navigating the future of inclusive clinical trials
DESCRIPTION:Decentralized clinical trials have emerged as a promising approach to overcome traditional barriers\, enhance representation\, and improve the quality of research by bringing biomedical studies directly into communities. However\, recent policy changes under the Trump administration\, including the removal of FDA guidance on clinical trial diversity\, have raised concerns about the future of inclusive research. \n\n\n\nRead more about decentralizing clinical trials here. \n\n\n\nIn this webinar\, Ray Dorsey\, M.D.\, professor of neurology and the director of the Center for Human Experimental Therapeutics at the University of Rochester Medical Center in New York\, and Ramita Tandon\, Chief Clinical Trials Officer at Walgreens\, will discuss how decentralization is reshaping clinical research. They will explore the potential of pharmacy-based trials and strategies for increasing patient engagement. \n\n\n\nJoin us for an insightful conversation on the future of clinical trials and what it means for patients\, researchers\, and the healthcare industry. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nModerator\n\n\n\n\nJyoti Madhusoodanan\n\n\n\nAHCJ Civic Science FellowJyoti Madhusoodanan is AHCJ’s Civic Science Fellow\, covering race in health algorithms as part of a year-long fellowship funded by the Doris Duke Foundation. She is an independent science and health journalist who regularly covers biomedical research\, health equity\, clinical trials\, and the translation of basic research into clinical care. Her reporting on race adjustments in clinical algorithms was supported by a 2020 project fellowship from the MIT Knight Science Journalism program; reporting on other topics has received fellowship support from the Alicia Patterson Foundation\, the GSA Journalists in Aging program\, and others. Madhusoodanan is a senior contributor to Undark magazine and her work regularly appears in Nature\, Scientific American\, and other outlets. She also serves on the Board of Directors of the National Association of Science Writers. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nModerator\n\n\n\n\nLara Salahi\n\n\n\nAHCJ Health Equity Beat LeaderLara Salahi is AHCJ’s health beat leader on health equity. She’s an award-winning\, independent health journalist based in Boston\, whose work has appeared in local\, national and international television and digital news outlets. She is also the Distinguished Professor of Journalism at Endicott College in Beverley\, Mass. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nRay Dorsey\, M.D.\n\n\n\nProfessor of Neurology\, University of RochesterRay Dorsey\, M.D.\, is the David M. Levy Professor of Neurology at the University of Rochester and one of the world’s most read\, cited\, and followed neurologists. With his colleagues\, he wrote “Ending Parkinson’s Disease: A Prescription for Action\,” a book that provides a prescription for preventing and ending the world’s fastest growing brain disease. \n\n\n\nDorsey previously directed the University of Rochester’s Center for Health + Technology\, was elected chair of the international Huntington Study Group\, led the movement disorders division and neurology telemedicine at Johns Hopkins\, and consulted for McKinsey & Company. He completed his undergraduate degree at Stanford University and pursued his medical education and neurology training at the University of Pennsylvania where he also earned an MBA in healthcare management from the Wharton School. \n\n\n\nIn 2015\, the White House recognized Dorsey as a “Champion for Change” for Parkinson’s disease. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nRamita Tandon\n\n\n\nChief BioPharma Services Officer\, WalgreensAs Chief BioPharma Services Officer at Walgreens\, Ramita Tandon is responsible for leading and driving growth for the Company’s biopharma services\, which includes Walgreens Clinical Trials. In her role\, Ramita works across the healthcare and life sciences industries to enable next-generation clinical trials\, with the goal of making treatments equitable and accessible to patients. \n\n\n\nRamita brings more than 25 years of leadership and operational experience across a portfolio of industry-leading businesses in real-world evidence and patient-centered health outcomes. Since spearheading the launch of Walgreens Clinical Trials in June 2022\, Ramita and her team have been working to make clinical research an inherent care option for patients across the nation when the standard of therapy is not a viable option.  \n\n\n\nThrough its tailored efforts and collaboration with biopharma companies\, Ramita and her team have connected with more than 17 million people for potential recruitment into a sponsor-led clinical trial\, with that number growing daily. Research shows that only 5% of the U.S. population participates in clinical trials and nearly 80% of trials fail to meet their enrollment goals in the timeline presented\, which often contributes to delays in getting novel therapies to patients.  \n\n\n\nUltimately\, Ramita and her team’s main goal is to bring community pharmacy-led clinical trials to patients quicker by meeting them where they want to be met…in their own communities.
URL:https://healthjournalism.org/decentralized-navigating-the-future-of-inclusive-clinical-trials/
CATEGORIES:Algorithms and Health Disparities,Event,Health Equity,Webinar
ATTACH;FMTTYPE=image/png:https://healthjournalism.org/wp-content/uploads/2025/02/Decentralized-clinical-trials-webinar-ad.png
END:VEVENT
END:VCALENDAR